Biofrontera Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Biofrontera kazanç ve gelirinin sırasıyla yıllık 57.3% ve 25.4% oranında artması tahmin edilirken, EPS'nin yıllık 64.6% oranında büyümesi bekleniyor.

Anahtar bilgiler

57.3%

Kazanç büyüme oranı

64.6%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.9%
Gelir büyüme oranı	25.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	31 Aug 2023

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:AI10 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	61	-10	N/A	N/A	1
12/31/2024	47	-11	N/A	1	2
12/31/2023	36	-25	N/A	-16	2
6/30/2023	29	-23	-28	-28	N/A
3/31/2023	28	-14	-18	-18	N/A
12/31/2022	29	-1	-16	-16	N/A
9/30/2022	28	-12	-29	-29	N/A
6/30/2022	28	-26	-24	-24	N/A
3/31/2022	29	-29	-25	-25	N/A
12/31/2021	24	-38	-27	-27	N/A
9/30/2021	24	-23	-6	-6	N/A
6/30/2021	22	-10	-6	-6	N/A
3/31/2021	19	-10	-9	-9	N/A
12/31/2020	19	-11	-12	-12	N/A
12/31/2019	26	-11	-38	-38	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AI10 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: AI10 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: AI10 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: AI10 şirketinin gelirinin (yıllık 25.4% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: AI10 şirketinin gelirinin (yıllık 25.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: AI10 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Biofrontera Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023

Biofrontera Inc. Affirms Guidance for 2023

Biofrontera Inc. Provides Preliminary Revenue Guidance for the Second Quarter, First Half and Full-Year of 2023

Forecast breakeven date pushed back to 2024

Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Forecast breakeven date moved forward to 2022

Recent updates

Biofrontera Inc. to Report Nine Months, 2024 Results on Nov 13, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces Database Lock of Phase 3 Study of Ameluz-Photodynamic Therapy in Treatment of Superficial Basal Cell Carcinoma

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Biofrontera Inc. to Report Q2, 2024 Results on Aug 14, 2024

Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Biofrontera Inc. to Report Q1, 2024 Results on May 15, 2024

Biofrontera Inc., Annual General Meeting, Jun 12, 2024

Biofrontera Inc. to Report Q4, 2023 Results on Mar 15, 2024

Biofrontera Inc. announced that it has received $8 million in funding

Biofrontera Inc. announced that it expects to receive $8 million in funding

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use

Nasdaq Determines to Grant Biofrontera Inc. an Extension of 180 Calendar Days from November 22, 2023 to Regain Compliance

Biofrontera Inc. has filed a Follow-on Equity Offering in the amount of $4.5 million.

Biofrontera Inc. to Report Q4, 2023 Results on Mar 06, 2024

Biofrontera Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Continued Listing Requirement Under Nasdaq Listing Rule 5550(b)(1)

Biofrontera Inc., Annual General Meeting, Dec 20, 2023

Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023

Biofrontera Inc. to Report Q3, 2023 Results on Nov 09, 2023

Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)

Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)

Biofrontera Inc. Affirms Guidance for 2023

Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-Pdt for the Treatment of Basal Cell Carcinoma

Biofrontera Inc. to Report Q2, 2023 Results on Aug 11, 2023

New minor risk - Profitability

Biofrontera Inc. Provides Preliminary Revenue Guidance for the Second Quarter, First Half and Full-Year of 2023

Biofrontera Inc. Appoints Heikki Lanckriet to Its Board of Directors

Biofrontera Announces 1-For-20 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Biofrontera Notifies Nasdaq Regarding its No Longer in Compliance with Nasdaq Listing Rule 5605(c)(2)(A)

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.33 profit in 1Q 2022)

Biofrontera Inc. Announces Resignation of Erica Monaco, Chief Executive Officer

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: US$0.024 loss per share (vs US$4.28 loss in FY 2021)

Less than half of directors are independent

Forecast breakeven date pushed back to 2024

Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Biofrontera Inc. to Launch Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk

Forecast breakeven date moved forward to 2022

Less than half of directors are independent

Biofrontera Inc. Revises Revenue Guidance for the Year 2022

Biofrontera Inc. to Report Q3, 2022 Results on Nov 14, 2022

Biofrontera Inc., Annual General Meeting, Dec 12, 2022

Biofrontera Inc. Names Fred Leffler as Chief Financial Officer

Biofrontera Inc. Reports Preliminary Product Revenues for the Third Quarter and Nine Months Ended September 30, 2022

Biofrontera Inc. Appoints Gerard Digirolamo as National Sales Director

Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.46 loss in 2Q 2021)

Biofrontera Inc. Provides Earnings Guidance for the Fiscal Year of 2022

Biofrontera Inc. to Report Q2, 2022 Results on Aug 12, 2022

Biofrontera Inc. Provides Revenue Guidance for the Second Quarter and Six Months Ended June 30, 2022

Biofrontera Inc.(NasdaqCM:BFRI) dropped from Russell Microcap Value Index

Biofrontera Inc. Appoints Kevin D. Weber to the Nominating and Corporate Governance, Audit and Compensation Committees

Biofrontera Inc. Appoints Kevin D. Weber to the Nominating and Corporate Governance, Audit and Compensation Committees

Biofrontera Inc. announced that it has received $9.40068 million in funding

Biofrontera Inc. announced that it expects to receive $9.40225 million in funding

First quarter 2022 earnings released: EPS: US$0.33 (vs US$0.44 loss in 1Q 2021)

Biofrontera Inc. Re-Affirms Earnings Guidance for 2022

Biofrontera Inc. to Report Q1, 2022 Results on May 13, 2022

Less than half of directors are independent

Full year 2021 earnings released: US$4.28 loss per share (vs US$479 loss in FY 2020)

Forecast to breakeven in 2023

High number of new and inexperienced directors

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin